Patents Assigned to Ipsen Pharma S.A.S.
  • Patent number: 9382306
    Abstract: The present invention relates to novel octapeptide compounds of general formula (I): H-2-Nal 1-cyclo(Cys2-Tyr3-AA4-Lys5-Val6-Cys7)-Thr8-NH2. Since these products have a good affinity for certain somatostatin receptor subtypes, they are particularly advantageous for treating pathological states or diseases in which one (or more) somatostatin receptor(s) is (are) involved. These compounds furthermore have physiochemical properties that make it possible to envisage them in diverse solutions for the formulation of medicaments, for example as a pharmaceutically acceptable carrier. The invention also relates to pharmaceutical compositions containing said products and to the use thereof for the preparation of a medicament.
    Type: Grant
    Filed: September 29, 2009
    Date of Patent: July 5, 2016
    Assignees: IPSEN PHARMA S.A.S., COMMISSARIAT A L'ENERGIE ATOMIQUE (CEA), LE CENTRE NATIONAL DE RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Marie-Thérèse Paternostre, Jean-Christophe Cintrat, Céline Valery, Stéphane Roux, Bernard Rousseau, Maarten Ijsselstijn, Roland Cherif-Cheikh, Franck Artzner
  • Publication number: 20160176925
    Abstract: The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as obesity, diabetes mellitus and sexual dysfunction.
    Type: Application
    Filed: February 29, 2016
    Publication date: June 23, 2016
    Applicant: Ipsen Pharma S.A.S.
    Inventors: Zheng Xin DONG, Daniel B. DEOLIVEIRA, Jeanne Mary COMSTOCK
  • Patent number: 9370520
    Abstract: The present invention relates to novel macrocylic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of LRRK2 (Leucine-Rich Repeat Kinase 2). Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicine or diagnostic agent, in particular for the treatment and/or diagnosis of diseases characterized by LRRK2 kinase activity such as neurological disorders including Parkinson's disease and Alzheimer's disease.
    Type: Grant
    Filed: June 23, 2015
    Date of Patent: June 21, 2016
    Assignee: IPSEN PHARMA S.A.S.
    Inventors: Jan Hoflack, Petra Blom
  • Patent number: 9352012
    Abstract: The invention relates to a process for the preparation of injectable pharmaceutical compositions for the sustained release of somatostatin analogues and to pharmaceutical compositions prepared according to the process. In a preferred aspect the process comprises the steps of combining lanreotide acetate and acetic acid, lyophilizing the resulting mixture only once, and hydrating the lyophilizate. Acetic acid may be added to a desired pH during the final step of the process.
    Type: Grant
    Filed: January 11, 2011
    Date of Patent: May 31, 2016
    Assignee: IPSEN PHARMA S.A.S.
    Inventors: Martin Montes, Thomas Ciaran Loughman, Chantal Roume, Roland Cherif-Cheikh
  • Patent number: 9314509
    Abstract: The present invention relates to improvements in compositions containing peptides that are ligands of one or more of the melanocortin receptors (MC-R), or pharmaceutically acceptable salts thereof, methods for preparing such compositions, and method of using such compositions to treat mammals. In particular, the present invention relates to a pharmaceutical composition comprising a pamoate salt of Ac-Arg-cyclo(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2 which is a ligand of the melanocortin receptor subtype 4 (MC4-R), and in which, after subcutaneous or intramuscular administration to a subject, the peptide forms a depot at physiological pH that is slowly dissolved and released into the body fluid and bloodstream. The present invention may further comprise an organic component such as dimethylacetamide (DMA) or polyethylene glycol (PEG) with an average molecular weight of lower than 1000.
    Type: Grant
    Filed: November 15, 2010
    Date of Patent: April 19, 2016
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Zheng Xin Dong, Jundong Zhang
  • Patent number: 9296783
    Abstract: The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as obesity, diabetes mellitus and sexual dysfunction.
    Type: Grant
    Filed: September 12, 2013
    Date of Patent: March 29, 2016
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Zheng Xin Dong, Daniel B. Deoliveira, Jeanne Mary Comstock
  • Patent number: 9259458
    Abstract: The present invention relates to at least one botulinum neurotoxin for treatment or prevention of pain associated with diabetic neuropathy wherein said botulinum neurotoxin is prepared for local administration, wherein the local administration is not in the central nervous system (CNS), and wherein pain is treated at a site distant to the site of administration.
    Type: Grant
    Filed: February 7, 2014
    Date of Patent: February 16, 2016
    Assignee: IPSEN PHARMA S.A.S.
    Inventors: Christine Favre, Michel Auguet, Piere-Etienne Chabrier De Lassauniere
  • Publication number: 20150366934
    Abstract: The present invention relates to peptide ligands of the melanocortin receptors, in particular the melancortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as insulin resistance.
    Type: Application
    Filed: September 3, 2015
    Publication date: December 24, 2015
    Applicant: IPSEN PHARMA S.A.S.
    Inventors: Heather A. Halem, Michael DeWitt Culler, Andrew A. Butler
  • Patent number: 9176119
    Abstract: The invention relates to a method for determining the kinetics of action of a cholinergic neurotoxin as well as a method for determining the quantity of neurotoxin in a sample.
    Type: Grant
    Filed: August 11, 2006
    Date of Patent: November 3, 2015
    Assignee: IPSEN PHARMA S.A.S.
    Inventors: José-Antonio Camara-Ferrer, Michael Auguet, Pierre-Etienne Chabrier De Lassauniere
  • Publication number: 20150290330
    Abstract: The present invention relates to novel somatostatin-dopamine chimeric analogs and their therapeutic uses for the inhibition, prevention, and/or treatment of neoplasia, neuroendocrine tumors, Cushing's disease/syndrome, and other conditions.
    Type: Application
    Filed: October 31, 2013
    Publication date: October 15, 2015
    Applicant: IPSEN PHARMA S.A.S.
    Inventors: Zheng Xin DONG, Yeelana SHEN, Sun Hyuk Kim
  • Patent number: 9155777
    Abstract: The present invention relates to peptide ligands of the melanocortin receptors, in particular the melanocortin-4 receptor, and as such, are useful in the treatment of disorders responsive to the activation of this receptor, such as insulin resistance.
    Type: Grant
    Filed: November 5, 2008
    Date of Patent: October 13, 2015
    Assignees: Ipsen Pharma S.A.S., Louisiana State University
    Inventors: Heather A. Halem, Michael Dewitt Culler, Andrew A. Butler
  • Patent number: 9133261
    Abstract: The invention comprises peptidyl analogs that possess agonist or antagonist ghrelin activity, along with therapeutic and non-therapeutic uses thereof.
    Type: Grant
    Filed: January 17, 2014
    Date of Patent: September 15, 2015
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Zheng Xin Dong, Yeelana Shen
  • Patent number: 9133262
    Abstract: The invention features somatostatin antagonists having a D-amino acid at the second residue.
    Type: Grant
    Filed: April 13, 2009
    Date of Patent: September 15, 2015
    Assignees: Ipsen Pharma S.A.S., The Administrators of the Tulane Educational Fund
    Inventors: David H. Coy, Barry Morgan, William Murphy
  • Publication number: 20150252092
    Abstract: There is provided a series of glucose-dependent insulinotropic polypeptide analog compounds, pharmaceutical compositions, and the use of the GIP polypeptide analog compounds as GIP-receptor agonists or antagonists for the treatment of GIP-receptor mediated conditions, such as non-insulin dependent diabetes mellitus and obesity.
    Type: Application
    Filed: May 20, 2015
    Publication date: September 10, 2015
    Applicant: IPSEN PHARMA S.A.S.
    Inventor: Zheng Xin DONG
  • Publication number: 20150252078
    Abstract: The present invention relates to novel somatostatin analogs, dimers thereof, and methods of using the same to treat various diseases. Naturally occurring somatostatins (SSTs), which are also known as somatotropin release-inhibiting factors (SRIFs), have diverse biological effects in many cells and organs 10 throughout the body. They are produced by normal endocrine, gastrointestinal, immune and neuronal cells, as well as by certain tumors (Patel, Y. C, Frontiers in Neuroendocrinology, 20(3): 157-198 (1999); Froidevaux, et al., Biopolymers, 66(3): 161-83 (2002)).
    Type: Application
    Filed: October 31, 2013
    Publication date: September 10, 2015
    Applicant: Ipsen Pharma S.A.S.
    Inventors: Zheng Xin Dong, Eric Ferrandis
  • Publication number: 20150252093
    Abstract: There is provided a novel series of analogues of glucose-dependent insulinotropic polypeptide compounds, pharmaceutical compositions containing said compounds, and the use of said compounds as GIP-receptor agonists or antagonists for treatment of GIP-receptor mediated conditions, such as non-insulin dependent diabetes mellitus and obesity.
    Type: Application
    Filed: May 20, 2015
    Publication date: September 10, 2015
    Applicant: IPSEN PHARMA S.A.S.
    Inventor: Zheng Xin DONG
  • Publication number: 20150218245
    Abstract: The present invention relates to a method of treating a transient impairment of the motility of the gastrointestinal system resulting from postoperative ileus in a patient wherein said method includes the step of administering a therapeutically effective amount of a peptidyl analog of ghrelin to said patient.
    Type: Application
    Filed: February 23, 2015
    Publication date: August 6, 2015
    Applicant: IPSEN PHARMA S.A.S.
    Inventors: Rakesh DATTA, Zheng Xin DONG
  • Patent number: 9096609
    Abstract: The present invention relates to novel macrocylic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of LRRK2 (Leucine-Rich Repeat Kinase 2). Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicine or diagnostic agent, in particular for the treatment and/or diagnosis of diseases characterized by LRRK2 kinase activity such as neurological disorders including Parkinson's disease and Alzheimer's disease.
    Type: Grant
    Filed: September 28, 2012
    Date of Patent: August 4, 2015
    Assignees: Ipsen Pharma S.A.S., Oncodesign S.A.
    Inventors: Jan Hoflack, Petra Blom
  • Patent number: 9080220
    Abstract: The present invention relates to a composition comprising: at least one botulinum neurotoxin, and at least one opiate derivative or its salt. The invention also relates to a product comprising at least one botulinum neurotoxin and at least one opiate derivative or its salt, as a combination product for simultaneous, separate or sequential therapeutic use in the treatment or prevention of pain and of neuromuscular disorders.
    Type: Grant
    Filed: June 11, 2007
    Date of Patent: July 14, 2015
    Assignee: IPSEN PHARMA S.A.S.
    Inventors: Michel Auguet, Christine Favre, Pierre-Etienne Chabrier De Lassauniere
  • Patent number: 9074014
    Abstract: A series of glucose-dependent insulinotropic polypeptide analog compounds, pharmaceutical compositions, and the use of the GIP polypeptide analog compounds as GIP-receptor agonists or antagonists for the treatment of GIP-receptor mediated conditions, such as non-insulin dependent diabetes mellitus and obesity.
    Type: Grant
    Filed: August 7, 2009
    Date of Patent: July 7, 2015
    Assignee: Ipsen Pharma S.A.S.
    Inventor: Zheng Xin Dong